JP2021534188A5 - - Google Patents
Info
- Publication number
- JP2021534188A5 JP2021534188A5 JP2021507982A JP2021507982A JP2021534188A5 JP 2021534188 A5 JP2021534188 A5 JP 2021534188A5 JP 2021507982 A JP2021507982 A JP 2021507982A JP 2021507982 A JP2021507982 A JP 2021507982A JP 2021534188 A5 JP2021534188 A5 JP 2021534188A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- composition according
- cancer
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719189P | 2018-08-17 | 2018-08-17 | |
| US62/719,189 | 2018-08-17 | ||
| US201862733380P | 2018-09-19 | 2018-09-19 | |
| US62/733,380 | 2018-09-19 | ||
| US201962808376P | 2019-02-21 | 2019-02-21 | |
| US62/808,376 | 2019-02-21 | ||
| US201962854701P | 2019-05-30 | 2019-05-30 | |
| US62/854,701 | 2019-05-30 | ||
| PCT/US2019/046852 WO2020037225A1 (en) | 2018-08-17 | 2019-08-16 | Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534188A JP2021534188A (ja) | 2021-12-09 |
| JP2021534188A5 true JP2021534188A5 (https=) | 2022-08-15 |
Family
ID=67841175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507982A Ceased JP2021534188A (ja) | 2018-08-17 | 2019-08-16 | ＮａＰｉ２ｂに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11407825B2 (https=) |
| EP (1) | EP3836972A1 (https=) |
| JP (1) | JP2021534188A (https=) |
| KR (1) | KR20210049122A (https=) |
| CN (1) | CN113194999A (https=) |
| AU (1) | AU2019320818A1 (https=) |
| BR (1) | BR112021002747A2 (https=) |
| CA (1) | CA3109790A1 (https=) |
| IL (1) | IL280867A (https=) |
| MX (1) | MX2021001924A (https=) |
| TW (1) | TW202035452A (https=) |
| WO (1) | WO2020037225A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| TW202035452A (zh) * | 2018-08-17 | 2020-10-01 | 美商梅爾莎納醫療公司 | 靶向ＮａＰｉ２ｂ之聚合物抗體－藥物共軛體和使用彼之方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2022235636A1 (en) * | 2021-05-03 | 2022-11-10 | Mersana Therapeutics, Inc. | Combination therapy of carboplatin and napi2b-targeted polymer antibody-drug conjugate for the treatment of ovarian cancer |
| US20230338569A1 (en) * | 2021-09-09 | 2023-10-26 | Mersana Therapeutics, Inc. | NaPi2b-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER |
| JP2025536308A (ja) * | 2022-10-18 | 2025-11-05 | テューブリス ゲーエムベーハー | 新規なＮａＰｉ２ｂ抗体を有する新規な抗体－薬物コンジュゲート、治療的方法、ならびにそれらの使用 |
| WO2025081282A1 (en) * | 2023-10-19 | 2025-04-24 | Zymeworks Bc Inc. | Anti-napi2b antibody-drug conjugates and methods of use |
| KR102764613B1 (ko) | 2024-03-28 | 2025-02-12 | 한양대학교 에리카산학협력단 | NaPi2b 특이적 CAR-T를 포함하는 난소암 치료용 약학 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3900534A1 (de) | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
| CH694588A5 (de) | 1999-02-09 | 2005-04-15 | Hoffmann La Roche | Menschliche intestinale Npt2B. |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| AU2003219665A1 (en) | 2002-01-15 | 2003-07-30 | Board Of Regents, The University Of Texas System | Napi type iib polypeptides and methods for making and using same |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| US8383799B2 (en) | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| US8802094B2 (en) | 2006-10-25 | 2014-08-12 | Wisconsin Alumni Research Foundation | Method of reducing phosphate absorption by administering orally an IgY anti-intestinal sodium phosphate cotransporter type 2B antibody |
| US8603474B2 (en) | 2008-01-29 | 2013-12-10 | Ludwig Institute For Cancer Research, Ltd. | Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| EP2240495B1 (en) | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| AU2009270988A1 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| JP5370826B2 (ja) | 2009-04-20 | 2013-12-18 | 株式会社パソロジー研究所 | 癌の組織型を判別するカクテル抗体、判別キット及び判別方法 |
| PH12012500982A1 (en) | 2009-11-30 | 2019-07-10 | Genentech Inc | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2) |
| WO2012006473A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| WO2012054110A2 (en) | 2010-07-07 | 2012-04-26 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| WO2012006474A2 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| KR102087850B1 (ko) * | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| ES2754397T3 (es) * | 2013-10-11 | 2020-04-17 | Asana Biosciences Llc | Conjugados de proteína-polímero-fármaco |
| US9808528B2 (en) * | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| AU2015358532C1 (en) * | 2014-12-03 | 2020-10-29 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| EP3365679B8 (en) | 2015-10-23 | 2021-03-10 | Roche Diagnostics GmbH | Methods of identifying an individual as to be treated by chemotherapy based on marker molecules and related uses |
| US10287259B2 (en) | 2016-03-14 | 2019-05-14 | The Penn State Research Foundation | Selenazolidine and thiazolidine compounds for treating cancer and other diseases |
| JP7137474B2 (ja) | 2016-03-15 | 2022-09-14 | メルサナ セラピューティクス，インコーポレイティド | ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法 |
| AU2018290330A1 (en) | 2017-06-22 | 2020-01-02 | Mersana Therapeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
| JP7279026B2 (ja) | 2017-09-20 | 2023-05-22 | メルサナ セラピューティクス インコーポレイテッド | Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法 |
| TW202035452A (zh) * | 2018-08-17 | 2020-10-01 | 美商梅爾莎納醫療公司 | 靶向ＮａＰｉ２ｂ之聚合物抗體－藥物共軛體和使用彼之方法 |
-
2019
- 2019-08-16 TW TW108129249A patent/TW202035452A/zh unknown
- 2019-08-16 WO PCT/US2019/046852 patent/WO2020037225A1/en not_active Ceased
- 2019-08-16 CN CN201980068682.0A patent/CN113194999A/zh active Pending
- 2019-08-16 AU AU2019320818A patent/AU2019320818A1/en not_active Abandoned
- 2019-08-16 US US16/542,642 patent/US11407825B2/en active Active
- 2019-08-16 MX MX2021001924A patent/MX2021001924A/es unknown
- 2019-08-16 EP EP19762538.7A patent/EP3836972A1/en not_active Withdrawn
- 2019-08-16 KR KR1020217008012A patent/KR20210049122A/ko not_active Abandoned
- 2019-08-16 JP JP2021507982A patent/JP2021534188A/ja not_active Ceased
- 2019-08-16 BR BR112021002747-5A patent/BR112021002747A2/pt not_active IP Right Cessation
- 2019-08-16 CA CA3109790A patent/CA3109790A1/en active Pending
-
2021
- 2021-02-15 IL IL280867A patent/IL280867A/en unknown
-
2022
- 2022-06-28 US US17/851,618 patent/US20220332815A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534188A5 (https=) | ||
| US10849899B2 (en) | Combination therapy comprising Varlitinib and an anticancer agent | |
| JP2025129187A5 (https=) | ||
| US20170035907A1 (en) | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab | |
| TWI795347B (zh) | 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌 | |
| JP2023511595A5 (https=) | ||
| TW202034959A (zh) | 抗體-藥物結合物與parp抑制劑之組合 | |
| WO2017087280A1 (en) | Methods of treating her2-positive cancer | |
| JP6255086B2 (ja) | 癌のための併用療法 | |
| JP2018527383A5 (https=) | ||
| JP2022519273A5 (https=) | ||
| JP2023539589A5 (https=) | ||
| JPWO2022270524A5 (https=) | ||
| JP6822980B2 (ja) | Ｈｅｒ２陽性転移性乳癌の治療方法 | |
| WO2025103377A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| JP2025517908A5 (https=) | ||
| JP2022531894A5 (https=) | ||
| CN120731228A (zh) | 肺癌的组合疗法 | |
| CN118871128A (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| JP7757339B2 (ja) | トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法 | |
| WO2025055589A1 (en) | Methods of treating cervical cancer using anti-her2 antibody-drug conjugates | |
| CN119607196A (zh) | 抗lag-3抗体与抗pd-1抗体的应用 | |
| RU2024137526A (ru) | Конъюгат b7-h4-направленного антитела-лекарственного средства для лечения рака | |
| JPWO2022270523A5 (https=) | ||
| JPWO2022019259A5 (https=) |